Skip to content

Deep Brain Stimulation of the Deep Cerebellar Nuclei for Refractory Tremor

Deep Brain Stimulation of the Deep Cerebellar Nuclei for Refractory Tremor

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07049003
Acronym
rT DBS
Enrollment
12
Registered
2025-07-03
Start date
2026-01-15
Completion date
2029-12-31
Last updated
2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Tremor, Tremor

Brief summary

This objective of this study is to document the safety and feasibility of electrical stimulation of the deep cerebellar nuclei for refractory tremor using the Medtronic Percept RC Deep Brain Stimulation System. The population will consist of patients that have either failed a prior intervention (Vim DBS or HIFU thalamotomy) or determined to not be suitable candidates for Vim DBS or HIFU thalamotomy because they have a cerebellar outflow or MS-related tremor. Those patients with a previous intervention, must have a prior diagnosis of ET, cerebellar outflow tremor, or MS-related tremor. Subjects without a previous intervention must have a diagnosis of cerebellar outflow tremor or MS-related tremor.

Interventions

DEVICEDeep Brain Stimulation

Deep Brain Stimulation of the Deep Cerebellar Nuclei

Sponsors

The Cleveland Clinic
Lead SponsorOTHER
Raynor Cerebellum Project
CollaboratorUNKNOWN
Medtronic
CollaboratorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

All subjects will receive open label deep brain stimulation implantation of the deep cerebellar nuclei

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 21 years and older; * Ability to give informed consent; * Diagnosis of ET, cerebellar tremor, or MS-related tremor with a failed a prior intervention (VIM DBS or HIFU thalamotomy) or determined to not be suitable candidates for VIM DBS or HIFU thalamotomy because they have a cerebellar outflow or MS-related tremor. * Tremor history of at least three years; * Tremor that is refractory to medical management; * A score of ≥24 on the Mini Mental State Examination; * Inability to successfully perform ADLs without assistance or has lost interest in social, professional, or personal activities due to tremor

Exclusion criteria

* Any other neurological condition that could reduce the safety of study participation including central nervous system vasculitis and intracranial malignancy * A condition that, in the opinion of the clinical investigator, would significantly increase the risk or interfere with study compliance, safety, or outcome; * A diagnosis of dementia; * Tremors due to other neurological conditions such as Parkinson's disease, dystonia, or other conditions not consistent with ET, cerebellar outflow tremor, or MS-related tremor. * Diagnosis of epilepsy; * Major active and untreated psychiatric illness that may interfere with study, such as psychotic disorders or severe personality disorders; * Untreated or inadequately treated depression defined by a score of 20 or greater on the Beck Depression Inventory-II at the time of enrollment; * At risk for suicide defined by a score greater or equal to 3 on the Columbia Suicide Severity Rating Scale (C-SSRS); * Pregnancy; * Unable to communicate with investigators or staff; * Surgical contraindications to DN DBS; * Contraindication to magnetic resonance (MRI) imaging, e.g., weight incompatible with scanner, implanted metallic devices or electrical devices (pacemaker, defibrillator, spinal cord stimulator, prior DBS) or intolerance to MRI contrast agent; * Enrolled in another device, biologic or pharmaceutical study within 30 days of consent in the current study, (i.e., patient cannot be enrolled if participation in another study was not completed at least 30 days prior to consent.); * Evidence of behavior(s) consistent with alcohol or substance abuse/dependence as defined by the criteria outlined in the DSM-V within the preceding six months; * Injection of botulinum toxins into the arm, neck or face within six months prior to baseline;

Design outcomes

Primary

MeasureTime frameDescription
The incidence and nature of treatment-related adverse eventsFrom DBS Implant Surgery through study completion, an average of 17 monthsThe accumulation of adverse events across all subjects

Secondary

MeasureTime frameDescription
Fahn Tolosa Marin Tremor Rating ScaleFrom DBS Implant Surgery through study completion, an average of 17 monthsAn objective measurement of the severity of tremor. A 32-part questionnaire that evaluates tremor severity by assigning a numerical value of 0-4 to the answers for 32 questions. Numerical values are added together for a total score. A higher score represents a more severe tremor than a lower score.
DBS-evoked potentialsFrom DBS Implant Surgery through study completion, an average of 17 monthsThe prevalence and strength of markers of electrophysiological activity across the cerebellothalamocorticomuscular (CTCM) network at rest and during tremor-eliciting motor behaviors.
4-8 HZ (theta) tremor related oscillationsFrom DBS Implant Surgery through study completion, an average of 17 monthsExamination of how the DN and VIM DBS (when present) modulate oscillatory activity and coupling across the CTCM circuit in relation to improvements in tremor control. A 4-8Hz (theta) tremor-related oscillation is observed consistently in the VIM during motor activity, which parallels the activity-dependent appearance of tremor in patients with ET.

Countries

United States

Contacts

CONTACTJeffrey Negrey, MA
negreyj2@ccf.org2163166896

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026